
    
      The study is a multicenter, US, open-label study consisting of two segments (A and B).
      Segment A is a minimum 1-week (maximum 4-week) screening period and Segment B is a 52-week,
      open-label period. All treated patients must complete a post-study telephone visit and a
      post-study office visit 3 days and 1 week, respectively, after intake of the last dose of
      study medication.
    
  